A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy (MEET URO 12)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519519-32-00

Acronym

MEET-URO 12

Enrollment

Registered

2025-01-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urothelial cancer

Brief summary

Progression free survival (PFS)

Detailed description

Proportion of objective answers, Duration of the answer, Global survival, Proportion of progression-free patients at 6 months from randomization., Safety and tolerability, Quality of life (patient-reported outcomes)

Interventions

DRUGZejula 100 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS)	—

Secondary

Measure	Time frame
Proportion of objective answers, Duration of the answer, Global survival, Proportion of progression-free patients at 6 months from randomization., Safety and tolerability, Quality of life (patient-reported outcomes)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026